

Biocon Biologics gets US FDA approval for Biosimilar Bevacizumab, expanding oncology portfolio

10 April 2025 | News

Jobevne is a recombinant humanised monoclonal antibody used to treat several different types of cancer



Biocon Biologics Ltd (BBL), a subsidiary of Bengaluru-based Biocon Ltd has announced that the US Food and Drug Administration (US FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use.

Jobevne, a recombinant humanised monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis, combating cancer by restricting blood supply to the tumor.

The approval of Jobevne expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said, "The US FDA approval of Jobevne (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the US and a strong addition to our robust oncology portfolio.